Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged < 12 Months

药代动力学 群体药代动力学 药效学 低磷血症 医学 人口 药理学 内科学 环境卫生
作者
Hiroki Okada,Nathalie Gosselin,L.H. Pheng,Nagaraju Poola,Emilia Quattrocchi,Matthew Hruska,Douglas Marsteller
标识
DOI:10.70534/jude7642
摘要

Objectives: Burosumab is a monoclonal antibody that increases serum phosphate in patients with X-linked hypophosphatemia (XLH) by targeting fibroblast growth factor 23 (FGF23) and is approved for the treatment of XLH in adult and pediatric patients in a number of countries. The objective of this analysis was to characterize the pharmacokinetics (PK) and pharmacokinetic/pharmacodynamic (PK/PD) relationship of burosumab in patients with XLH aged < 12 months using population pharmacokinetics (PPK) and population pharmacokinetic/pharmacodynamic (PPK/PD) modeling approaches.Methods: PPK and PPK/PD analyses were performed using data (3735 and 7786 serum samples for PK and PD [serum phosphate], respectively) from a pediatric study (NCT04188964) of patients with XLH aged < 12 months and data from 10 previously conducted clinical studies in patients with XLH aged 10 months to 12 years and 18 to 68 years. Phoenix NLME® Version 8.4 was used for nonlinear mixed effects modeling. Covariate effects were tested for significance in a stepwise manner using the likelihood ratio test. Verification of the models was performed using goodness-of-fit (GOF) plots and visual predictive checks (VPCs).Results: Burosumab PK following subcutaneous (SC) administration in patients with XLH aged < 12 months was described using a one-compartment model with time-varying body weight (WT) on apparent clearance (CL/F) and apparent volume of distribution (V/F) with a first-order rate of absorption, maturation function [1] on CL/F, and age effect on V/F. The estimated β (fractional change in CL/F in a typical full-term neonate at birth) was 0.250 and maturation half-life for CL/F was 1.74 years, which corresponded to 8.7 years to achieve full maturation. The age effect on V/F was parameterized as a power function with estimated exponent of 0.129. The PPK/PD model of burosumab following SC administration in patients with XLH aged < 12 months was described using a sigmoid maximum effect (Emax) model with baseline age on baseline serum phosphate level (E0), time-varying WT on serum burosumab concentration to reach 50% of Emax (EC50), and time-varying age on Emax. All covariates were included in the model using a power function. The typical values of E0, EC50, and Emax for infant patients aged 0.734 years weighing 8.85 kg are 2.88 mg/dL, 1960 ng/mL, and 0.600 mg/dL, respectively. The GOF plots and VPCs for the PPK and PPK/PD models verified that both models were acceptable to be selected as a final model.Conclusions: The PK and PD of burosumab in patients with XLH aged < 12 months were adequately characterized using these PPK and PPK/PD models. Additional parameters associated with age were included in order to capture the new data from infants and are likely associated with the rapid maturation and changes in renal physiology at this age. The PPK/PD model can be used to support the dosing of burosumab in pediatric patients with XLH aged < 12 months.Study funded by Kyowa Kirin IncCitations: [1] Robbie GJ et al. Antimicrob Agents Chemother 2012;56:4927.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
默默的走过完成签到,获得积分10
刚刚
axiang完成签到,获得积分10
2秒前
2秒前
shuyiWang发布了新的文献求助10
2秒前
焕得完成签到,获得积分10
2秒前
younger发布了新的文献求助10
3秒前
4秒前
传奇3的应助被MAX采纳,获得10
5秒前
万能图书馆的应助被axiang采纳,获得10
6秒前
stackheap发布了新的文献求助10
6秒前
天天天才完成签到,获得积分10
6秒前
6秒前
shirley完成签到,获得积分10
7秒前
体贴火发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
失眠枫发布了新的文献求助10
9秒前
rui2820完成签到,获得积分10
9秒前
CipherSage的应助被科研通管家采纳,获得10
10秒前
Maestro_S的应助被科研通管家采纳,获得30
10秒前
一颗苹果的应助被科研通管家采纳,获得10
10秒前
10秒前
初景发布了新的文献求助10
10秒前
隐形曼青的应助被科研通管家采纳,获得10
10秒前
领导范儿的应助被科研通管家采纳,获得30
11秒前
Lucas的应助被科研通管家采纳,获得10
11秒前
慕青的应助被科研通管家采纳,获得10
11秒前
Orange的应助被科研通管家采纳,获得30
11秒前
11秒前
一颗苹果的应助被科研通管家采纳,获得10
11秒前
11秒前
汉堡包的应助被科研通管家采纳,获得10
11秒前
null的应助被科研通管家采纳,获得10
12秒前
隐形曼青的应助被科研通管家采纳,获得10
12秒前
12秒前
乐乐的应助被科研通管家采纳,获得10
12秒前
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573478
关于积分的说明 21831914
捐赠科研通 7781737
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962